{
    "relation": [
        [
            "",
            "Lapatinib With Paclitaxel",
            "Placebo With Paclitaxel"
        ],
        [
            "Description",
            "Participants received lapatinib 1500 mg orally OD with paclitaxel 175 m^2 IV over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal.",
            "Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal."
        ]
    ],
    "pageTitle": "Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00075270?sect=Xk0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981460.12/warc/CC-MAIN-20150728002301-00131-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 853773947,
    "recordOffset": 853759086,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups A total of 580 participants were enrolled and randomized to treatment; however one participant withdrew from the study before taking any medication. Thus, only 579 participants were included in the Intent-to-Treat Population (comprised of all randomized participants who had received at least one dose of randomized therapy [lapatinib or placebo]). Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Paclitaxel Drug: GW572016 (Lapatinib) Interventions: Neoplasms, Breast Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Lapatinib With Paclitaxel \u00a0 \u00a0 Placebo With Paclitaxel \u00a0 STARTED \u00a0 \u00a0 291 \u00a0 \u00a0 288 \u00a0 Missing \u00a0 \u00a0 26 [1] \u00a0 13 [1] COMPLETED \u00a0 \u00a0 5 \u00a0 \u00a0 4 \u00a0 NOT COMPLETED \u00a0 \u00a0 286 \u00a0 \u00a0 284 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 28 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 21 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 25 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}